RxDoctor Payments Data

Alan Freeman, MD

Neurology · Atlanta, GANPI 1124132766

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GE HealthCare accounts for 68.1% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for neurology clinicians in GA, where the typical reported total is $1,471.

$58in general payments, 2019–2025

Across 3 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$40
  • Merz Pharmaceuticals, LLC$19
$32,967in research payments, 2019–2025

Across 21 payments — averaging $1569.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • MDD US Operations, LLC$18K
  • Neurocrine Biosciences, Inc.$15K

What the payments were for

  • Food & beverage$58100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GE HealthCare2$40
Merz Pharmaceuticals, LLC1$19

How this compares

$58 in reported general payments places this provider in the 15th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia →

Medicare billing

Part B allowed, 2024
$262,927
Medicare patients
242
Services billed
29,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4611$388,536
AustedoDeutetrabenazine12$157,878
NuplazidPimavanserin Tartrate28$137,868
IngrezzaValbenazine Tosylate12$101,323
Carbidopa-LevodopaCarbidopa/Levodopa599$31,313
RytaryCarbidopa/Levodopa13$30,797
NeuproRotigotine18$17,912
Entacapone45$8,699
Rasagiline Mesylate56$8,655
Rivastigmine37$8,033
Carbidopa-Levodopa ErCarbidopa/Levodopa162$6,258
AmantadineAmantadine Hcl100$4,858
Primidone100$4,783
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone24$4,262
Selegiline Hcl23$2,023

Paid to pharmacies, not to this prescriber.

Other neurology in Atlanta

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →